Your session is about to expire
← Back to Search
Venetoclax + Obinutuzumab for Chronic Lymphocytic Leukemia (ReVenG Trial)
ReVenG Trial Summary
This trial will assess how well VenG works and how safe it is in adult participants with CLL who were previously treated with VenG.
ReVenG Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowReVenG Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 389 Patients • NCT02005471ReVenG Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- It's been over 24 months since my last venetoclax dose for Cohort 1, or 12-24 months for Cohort 2, and my disease progressed after first-line treatment.I completed VenG as my first treatment and my cancer responded well.It's been over 24 months since my last venetoclax dose for Cohort 1, or 12-24 months for Cohort 2, and my disease progressed after first-line VenG treatment.I've had treatment for CLL after my venetoclax and anti-CD20 therapy.I have chronic lymphocytic leukemia needing treatment based on iwCLL 2018 criteria.I completed a specific treatment for my cancer and it improved.I have chronic lymphocytic leukemia needing treatment, as per iwCLL 2018.
- Group 1: Cohort 1 - venetoclax + obinutuzumab
- Group 2: Cohort 2 - venetoclax + obinutuzumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Could you please list other research that has been done on Venetoclax?
"Venetoclax was first researched in 2012 at CHU de Dijon. To date, there have been 99 completed studies with 291 more currently underway. Many of these trials are based out of Duluth, Minnesota."
Are new participants being signed up for this research project at this time?
"This study, which is currently recruiting participants, was originally posted on 3/28/2022 and most recently updated on 11/9/2022."
Could you inform me as to how many people are enrolled in this clinical trial?
"Affirmative, the clinical trial is recruiting participants. According to information on clinicaltrials.gov, the posting date was March 28th, 2022 and the most recent update was November 9th, 2022. They are looking for 75 individuals across 14 sites."
For what condition is Venetoclax most often given to patients?
"haematologic malignancies including small lymphocytic lymphoma, chronic lymphocytic leukemia (cll), and lymphoid leukemia can all be treated using Venetoclax."
Is this trial only taking place in North America?
"There are currently 14 clinical trial sites recruiting for this study, including St. Luke's Hospital of Duluth /ID# 250021 in Duluth, Moores Cancer Center at UC San Diego /ID# 230157 in La Jolla, and Fox Chase Cancer Center /ID# 246851 in Philadelphia."
Does Venetoclax put patients at risk?
"Venetoclax is still in Phase 2 of clinical trials, so there is only limited data supporting its safety."
Who else is applying?
What state do they live in?
How old are they?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger